Amgen, Novartis Set to Launch Migraine Drug Aimovig Next Week after FDA Approval
Amgen and Novartis are set to commercially launch the first calcitonin gene-related peptide (CGRP) receptor inhibitor in the U.S. next week following FDA approval yesterday